[Proceedings: Rifampicin adverse effects in intermittent therapy].
D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000627:therapeutic use; D004338:Drug Combinations; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011693:Purpura / Q000139:chemically induced; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D013307:Streptomycin / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy
D000636:Aminosalicylic Acids; D004338:Drug Combinations; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin
Neue Probleme durch Rifampicin-Nebenwirkungen bei intermittierender Therapie.